Mark Chapman

Long only, contrarian, event-driven
Mark Chapman
Long only, contrarian, event-driven
Contributor since: 2013
Valuing Acadia Pharmaceuticals
Esperion Therapeutics: Too Much Uncertainty To Go Long
Antares Pharma: Why I'm Still Long
Tailwinds Forming For Nuance
Unilife Q3 2015 Earnings Preview
Aerie Pharma: Was Rocket 1 Really A Failure?
Why I Was Wrong About Esperion, But Is It A Buy Now?
Aerie Pharma: Finding Value In The Ophthalmic Space
Unilife: Big Potential, Bigger Risks
Antares Pharma: Preparing For An Inflection Point
Update: Nuance Q4 And FY 2014 Earnings